ReviewHematological oncology2025
Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target.
Review in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Article
- Secondary Genetic Events and Their Relationship toCancers · 2025Article
- Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?European journal of haematology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mantle cell lymphoma (MCL) is a B-cell malignancy characterized by t(11;14)(q13;q32) translocation and heterogeneous clinical behavior. Advances in risk stratification enabled the distinction of conventional MCL (cMCL) from non-nodal MCL (nnMCL) subtypes, which presents with distinct biological and clinical features. Prognostic tools such as MIPI/MIPI-c, Ki-67 expression, and TP53 mutation/deletion status have enhanced risk assessment, while new genomic alterations including 17p deletion, CDKN2A loss are emerging as a new prognostic factors. Above all, TP53 disruption remains the major adverse factor, associated with poor outcomes despite new combination therapies. Although recent clinical trials are exploring innovative targeted strategies, the effective management of high-risk MCL remains challenging till now. Minimal residual disease (MRD) monitoring is now emerging as a dynamic prognostic tool, offering potential for treatment adaptation. The integration of molecular and clinical predictors into personalized therapeutic strategies along with MRD monitoring could represent the basis of the future algorithm of MCL management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.